Cytokinetics. has been granted a patent for methods to treat heart failure using the cardiac sarcomere activator omecamtiv mecarbil. The methods involve adjusting dosage based on plasma concentration, with specific dosing guidelines for varying concentration levels to optimize treatment efficacy. GlobalData’s report on Cytokinetics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Cytokinetics, NSAID cancer drugs was a key innovation area identified from patents. Cytokinetics's grant share as of June 2024 was 41%. Grant share is based on the ratio of number of grants to total number of patents.
Method for treating heart failure using cardiac sarcomere activator
The granted patent US11986474B1 outlines a method for treating heart failure using a cardiac sarcomere activator (CSA), specifically omecamtiv mecarbil or its pharmaceutically acceptable forms. The treatment protocol involves an initial administration of 37.5 mg of the CSA twice daily for a minimum of two weeks. Following this initial period, the dosage is adjusted based on the subject's plasma concentration of the CSA, which is measured approximately 2-4 weeks after the first dose. The second dose level varies according to the plasma concentration: if it is below 300 ng/mL, the dosage increases to 50 mg twice daily; if it falls between 300 ng/mL and 750 ng/mL, it remains at 37.5 mg twice daily; and if it exceeds 750 ng/mL, the dosage is reduced to 25 mg twice daily.
The patent further specifies that the treatment is particularly applicable to subjects with chronic heart failure, including those classified under New York Heart Association Class II or III, and those with a left ventricular ejection fraction of 40% or lower. Additionally, it notes that subjects with NT-proBNP concentrations of at least 1000 pg/mL may also benefit from this treatment. The method emphasizes the importance of monitoring plasma concentrations to optimize dosing and achieve target levels between 300 ng/mL and 750 ng/mL during the second treatment phase. The CSA is administered orally, and the claims include various specifics regarding the timing and dosage adjustments based on individual patient responses.
To know more about GlobalData’s detailed insights on Cytokinetics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
